FMR LLC Files Schedule 13G Regarding Xenon Pharmaceuticals
FMR LLC has filed a Schedule 13G form indicating a change in its ownership stake in Xenon Pharmaceuticals.
Stocks · News reference
Alpha Buying: 4 Biotech Stocks Insiders Are Betting On
I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity is enormous.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NeOnc Technologies Q3 EPS $(0.28) Misses $(0.24) Estimate
NeOnc Technologies Holdings, Inc. Files Form 10-Q for Period Ending September 30, 2026
NeOnc Technologies Holdings, Inc. submitted its quarterly financial report (Form 10-Q) to the SEC for the period ending September 30, 2026.
Relmada Therapeutics Management to Participate in Jefferies Global Healthcare Conference
Relmada Therapeutics announced that its CEO and CFO will participate in the Jefferies Global Healthcare Conference in London from November 16-19, 2026.
Xenon Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Xenon Pharmaceuticals Inc. announced that it will present at four investor conferences during the fourth quarter of 2026.
8-K filing — NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Filed: 2026-11-03 AccNo: 0001829126-26-011937 Size: 211 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits